LOXL2 and neoplasm: In the MDA-MB-231 metastatic breast cancer cell line, a link between RAMP3 and LOXL2 has been reported; the blockade of LOXL2 promoted a mesenchymal-to-epithelial transition in breast cancer cells, a decreased invasive phenotype, and RAMP3 expression, leading to a reduced tumor development and tumor microvessel density when compared with controls [291].